Literature DB >> 11587078

Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation.

A Asea1, R Mallick, S Lechpammer, G Ara, B A Teicher, S Fiorentino, M A Stevenson, S K Calderwood.   

Abstract

It has previously been demonstrated that hyperthermia can activate prostaglandin synthesis and that prostaglandins are protective against hyperthermia. This study examined the use of inhibitors of prostaglandin synthesis on the response of prostate tumours to hyperthermia. The non-steroidal anti-inflammatory drugs (NSAID) ibuprofen and sulindac, known cyclooxygenase inhibitors that inhibit prostaglandin production, were effective hyperthermia sensitizers and augmented growth delay of DU-145 and PC-3 prostate tumours to combined radiation and hyperthermia treatment protocols. Pre-treatment of mice with ibuprofen and sulindac at hyperthermia sensitizing doses resulted in significant (p < 0.01) inhibition of hyperthemia-induced serum prostaglandin E2. These findings indicate that NSAID may have both sensitizing effects on prostate tumour growth and may function by inhibiting prostaglandin synthesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587078     DOI: 10.1080/02656730110058600

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  3 in total

1.  Surface expression of Hsp25 and Hsp72 differentially regulates tumor growth and metastasis.

Authors:  María A Bausero; Diana T Page; Eduardo Osinaga; Alexzander Asea
Journal:  Tumour Biol       Date:  2004 Sep-Dec

2.  Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells.

Authors:  Martin Scheer; Uta Drebber; Kai Breuhahn; Christoph Möckel; Tobias Reuther; Michael Kern; Joachim E Zöller
Journal:  Oral Maxillofac Surg       Date:  2010-03

3.  A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease.

Authors:  Punit Kaur; Ganachari M Nagaraja; Hongying Zheng; Dawit Gizachew; Moses Galukande; Sunil Krishnan; Alexzander Asea
Journal:  BMC Cancer       Date:  2012-03-27       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.